Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053059 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
A Phase 2 study of Acute Lymphocytic Leukemia (ALL), sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07053059 is a Phase 2 study of Acute Lymphocytic Leukemia (ALL) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07053059, a Phase 2 study of Acute Lymphocytic Leukemia (ALL), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Conditions Studied
Interventions
- DRUG Obecabtagene autoleucel
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2030-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053059
The ClinicalTrials.gov registry entry for NCT07053059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Lymphocytic Leukemia (ALL) appearing as the primary indexed condition, and to 1 intervention - of which Obecabtagene autoleucel is the first listed.
NCT07053059 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07053059 about?
NCT07053059 is a clinical study titled "Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)". The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
What is the current status of trial NCT07053059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08-26. Estimated completion is 2030-05-31.
What conditions does trial NCT07053059 study?
This clinical trial studies the following conditions: Acute Lymphocytic Leukemia (ALL).
What interventions are being tested in trial NCT07053059?
The interventions under investigation include: Obecabtagene autoleucel (DRUG).
Who is sponsoring clinical trial NCT07053059?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053059 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphocytic Leukemia (ALL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
RECRUITING · NA
-
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.